VIDEO: Rebyota effective in prevention of recurrent C. diff, even in higher risk patients
Click Here to Manage Email Alerts
PHILADELPHIA — Rebyota was safe and effective at 8 weeks and up to 6 months in patients with recurrent Clostridioides difficile infection, many of whom had other gastrointestinal comorbidities and risk factors, according to data presented.
“We showed a significant decrease in recurrence rates of Clostridioides difficile in a real-world population,” Timothy E. Ritter, MD, a gastroenterologist at GI Alliance in Southlake, Texas, told Healio. “It was tolerated extremely well.”
With limited data on the effectiveness of Rebyota (fecal microbiota, live-jslm; Ferring Pharmaceuticals) outside of clinical trials, Ritter and colleagues conducted a multicenter, retrospective study of 67 patients (median age, 74 years; 47% women) with recurrent C. difficile infection who were treated in-clinic with Rebyota between February 2023 and May 2024. Patients were assessed 8 weeks and 6 months after treatment.
Ritter noted that many of the patients had increased risk factors for recurrent C. difficile infection, including older age, proton pump inhibitor use, other GI diseases and a history of multiple recurrences.
According to results presented at the ACG Annual Scientific Meeting, 77.6% of patients were recurrence-free at 8 weeks, and of 30 patients who completed the 6-month follow-up, 86.7% sustained response. In addition, those with inflammatory bowel disease did not experience recurrence at either timepoint.
“This is a very patient friendly and helpful treatment to prevent recurrence of what we all know is an extremely debilitating disease in many patients,” Ritter said.
Collapse
Ritter TE, et al. Real-world experience with microbiota treatment for the prevention of recurrent Clostridioides. Presented at: ACG Annual Scientific Meeting; Oct. 25-30, 2024; Philadelphia (hybrid meeting).
Read more about
Click Here to Manage Email Alerts